atenolol

Brand: Tenormin

⚠ BBW Prototype: metoprolol-succinate
Drug Class: beta-blocker
Drug Family: antihypertensive
Subclass: selective beta-1 blocker (hydrophilic)
Organ Systems: cardiovascular

Mechanism of Action

Cardioselective beta-1 antagonist; hydrophilic — does not cross BBB; reduced CNS side effects.

beta-1 adrenergic receptor

Indications

  • hypertension
  • angina
  • post-MI

Contraindications

  • severe bradycardia
  • high-degree AV block
  • cardiogenic shock
  • decompensated HF

Adverse Effects

Common

  • bradycardia
  • fatigue
  • cold extremities

Serious

  • bronchospasm
  • heart block

Pharmacokinetics (ADME)

Absorption 50% oral bioavailability; not affected by food
Distribution hydrophilic — low CNS penetration
Metabolism minimal hepatic; excreted largely unchanged
Excretion renal 85%
Half-life 6-7 hours
Onset 1 hour
Peak 2-4 hours
Duration 24 hours
Protein Binding 6-16%
Vd 0.7 L/kg

Drug Interactions

Drug / Agent Mechanism Severity
verapamil/diltiazem additive AV block major
clonidine rebound hypertension on discontinuation major

Nursing Considerations

  1. Hydrophilic — less insomnia and depression than lipophilic beta-blockers
  2. Requires dose adjustment in renal impairment
  3. Once-daily dosing
  4. ASCOT trial: inferior to amlodipine-based regimen for CV outcomes in hypertension

Clinical Pearls

  • Hydrophilic — favored in patients with CNS-related beta-blocker side effects (insomnia, nightmares)
  • NOT preferred over succinate for HFrEF
  • Requires renal dose adjustment unlike lipophilic agents

Safety Profile

Pregnancy use-with-caution
Lactation use-with-caution
Renal Adjustment Required
Hepatic Adjustment Not required
TDM Not required

Concordance Terms

Cross-referenced clinical concepts — click any term to see all content where it appears.